FDA Gives Approval for First-of-Its-Kind Device

FDA gives approval for first-of-its-kind device

FRANKFORT, Ky. (KT) – The U.S. Food and Drug Administration (FDA) has approved a first-of-its-kind device for the treatment of adult patients who have locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a portable, non-invasive device that delivers alternating electrical fields, known as tumor treating fields (TTFields), to the abdomen. TTFields work by physically disrupting the rapid cell division that is characteristic of…

New FDA-Approved Device Uses Electric Fields to Treat Pancreatic Cancer

Learn more about the newly approved wearable treatment that disrupts pancreatic cancer tumor growth while letting patients continue daily life at home.

FDA Reassesses Food Preservative, Updates Hormone Therapy Warnings, and Approves New Pancreatic Cancer Device

What This Means for You Food Safety: The FDA has launched a new review of the food preservative BHA to determine whether it remains safe under current uses. Women’s Health: Risk statements related to cardiovascular disease, breast cancer, and probable dementia have been removed from the boxed warnings on certain menopausal hormone therapy products. Cancer Treatment: A first-of-its-kind, wearable device for locally advanced pancreatic cancer has…

FDA approves Israeli development for pancreatic cancer treatment

The Israeli company Novocure announced the approval by the US Food and Drug Administration of another of its products for the treatment of pancreatic cancer. Novocure was based on the late Professor Yoram Palti’s pioneering invention for treating cancer by directing electric fields at the tumor to prevent cells in the tumor from dividing. The […]